Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Neurocrine Biosciences, Inc. (NBIX) vs Dr. Reddy's Laboratories Ltd (RDY)

Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Ltd are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $14.1B against $10.0B — 1.4× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 19.6× against 30.8×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against −11.6%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs 9.81%) and the higher return on invested capital (15.0% vs 5.89%). Across the 22 metrics below, Neurocrine Biosciences, Inc. leads on 16 and Dr. Reddy's Laboratories Ltd on 6.

Valuation

Metric NBIX RDY Drug Manufacturers Specialty & Generic median
P/E 19.63 30.85 20.14
P/S 4.14 2.79 2.25
P/B 3.78 2.35 1.90
Price to free cash flow 16.06 69.03 16.54
EV/EBITDA 16.65 15.92 12.29
EV/Sales 4.11 2.76 2.56
Earnings yield 5.09% 3.24% (2.99%)
Free cash flow yield 6.23% 1.45% 0.00%

Profitability

Metric NBIX RDY Drug Manufacturers Specialty & Generic median
Gross margin 97.94% 50.00% 53.94%
Operating margin 23.56% 10.91% 0.00%
Net margin 20.91% 9.81% 0.00%
Free cash flow margin 25.80% 4.05% 0.00%
Return on equity 22.09% 8.21% (0.40%)
Return on assets 15.26% 5.55% (3.32%)
Return on invested capital 15.04% 5.89% 0.00%

Growth

Metric NBIX RDY Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 34.42% (11.60%) 10.01%
EPS growth (last fiscal year) 41.95% (30.38%) —
Revenue growth, 5-year CAGR 22.29% 6.66% 6.74%
Net income growth, 5-year CAGR 3.28% 14.08% 0.00%

Health

Metric NBIX RDY Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.19 0.05
Current ratio 1.87 1.90 2.31
Net debt to EBITDA (2.33) (0.15) 0.85

Dividend

Metric NBIX RDY Drug Manufacturers Specialty & Generic median
Dividend yield — 0.66% 1.70%
Payout ratio 0.00 0.14 0.00

Size

Metric NBIX RDY Drug Manufacturers Specialty & Generic median
Market cap 14.12b 10.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack